Patient views on long acting HIV treatment: Cabotegravir plus rilpivirine as maintenance therapy (ATLAS 48 week results)

被引：0

作者：

Murray, M. ^{[1
]}

Antela, A. ^{[2
]}

Mills, A. ^{[3
]}

Chounta, V. ^{[1
]}

Huang, J. ^{[4
]}

Jaeger, H. ^{[5
,6
]}

Khuong-Josses, M-A. ^{[7
]}

Hudson, K. ^{[8
]}

Spreen, W. ^{[8
]}

Williams, P. ^{[9
]}

Margolis, D. M. ^{[8
]}

机构：

[1] ViiV Healthcare, Brentford, England

[2] Complejo Hosp Univ Santiago, La Coruna, Spain

[3] Southern Calif Mens Med Grp, West Hollywood, CA USA

[4] GlaxoSmithKline, Mississauga, ON, Canada

[5] MUC Res GmbH, Munich, Germany

[6] MVZ Karlspl, HIV Res & Clin Care Ctr, Munich, Germany

[7] Hop Delafontaine, St Denis, Reunion, France

[8] ViiV Healthcare, Res Triangle Pk, NC USA

[9] Janssen Res & Dev, Beerse, Belgium

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2019年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

MOAB0103

引用

页码：2 / 2

页数：1

共 50 条

[1] Long-acting cabotegravir plus rilpivirine as maintenance therapy: ATLAS week-48 results
Margolis, D. A.
Swindells, S.
Andrade-Villanueva, J-F
Richmond, G. J.
Rizzardini, G.
Baumgarten, A.
Masia, M. D. M.
Latiff, G.
Pokrovsky, V.
Mrus, J. M.
Huang, J. O.
Hudson, K. J.
Smith, K. Y.
Williams, P.
Spreen, W. R.
[J]. HIV MEDICINE, 2019, 20 : 20 - 21
[2] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
Swindells, S.
Lutz, T.
Van Zyl, L.
Porteiro, N.
Benn, P.
Huang, J.
Harrington, C.
Hove, K.
Ford, S.
Talarico, C.
Chounta, V.
Crauwels, H.
Van Solingen-Ristea, R.
Vanveggel, S.
Margolis, D.
Smith, K.
Vandermeulen, K.
Spreen, W.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 19 - 21
[3] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results
Swindells, Susan
Lutz, Thomas
Van Zyl, Lelanie
Porteiro, Norma
Benn, Paul
Huang, Jenny O.
Harrington, Conn M.
Hove, Kai
Ford, Susan L.
Talarico, Christine L.
Chounta, Vasiliki
Crauwels, Herta
Van Solingen-Ristea, Rodica
Vanveggel, Simon
Margolis, David A.
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
Baum, Alexander
[J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S8
[4] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
Margolis, D.
Podzamczer, D.
Stellbrink, H-J
Lutz, T.
Angel, J.
Richmond, G.
Clotet, B.
Gutierrez, F.
Sloan, L.
Griffith, S.
St Clair, M.
Dorey, D.
Ford, S.
Mrus, J.
Crauwels, H.
Smith, K.
Williams, P.
Spreen, W.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[5] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Rizzardini, Giuliano
Overton, Edgar T.
Orkin, Chloe
Swindells, Susan
Arasteh, Keikawus
Gorgolas Hernandez-Mora, Miguel
Pokrovsky, Vadim
Girard, Pierre-Marie
Oka, Shinichi
Andrade-Villanueva, Jaime F.
Richmond, Gary J.
Baumgarten, Axel
Masia, Mar
Latiff, Gulam
Griffith, Sandy
Harrington, Conn M.
Hudson, Krischan J.
St Clair, Marty
Talarico, Christine L.
Patel, Parul
Cutrell, Amy
Van Eygen, Veerle
D'Amico, Ronald
Mrus, Joseph M.
Wu, Sterling
Ford, Susan L.
Chow, Ken
Roberts, Jeremy
Wills, Angela
Walters, Nicola
Vanveggel, Simon
Van Solingen-Ristea, Rodica
Crauwels, Herta
Smith, Kimberly Y.
Spreen, William R.
Margolis, David A.
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
[6] Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results
Orkin, C.
Arasteh, K.
Hernandez-Mora, M. G.
Pokrovsky, V.
Overton, E. T.
Girard, P-M
Oka, S.
D'Amico, R.
Dorey, D.
Griffith, S.
Margolis, D. A.
Williams, P.
Parys, W.
Spreen, W. R.
[J]. HIV MEDICINE, 2019, 20 : 6 - 7
[7] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
Orkin, C.
Oka, S.
Philibert, P.
Brinson, C.
Bassa, A. C.
Gusev, D.
Degen, O.
Gonzalez Garcia, J.
D'Amico, R.
Dorey, D.
Griffith, S.
Margolis, D. A.
St Clair, M.
Williams, P.
Spreen, W. R.
[J]. HIV MEDICINE, 2020, 21 : 14 - 14
[8] Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results
Benn, P.
Quercia, R.
Hudson, K.
Wang, Y.
Chounta, V.
Talarico, C.
Ford, S.
Cutrell, A.
Margolis, D.
Van Solingen-Ristea, R.
Vanveggel, S.
Van Eygen, V.
Polli, J.
de Ruiter, A.
Smith, K.
Spreen, W.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 28 - 29
[9] Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir plus rilpivirine in the phase IIIb ATLAS-2M study
Chounta, V.
Overton, E.
Noe, S.
Swindells, S.
Negredo, E.
D'Amico, R.
Harrington, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Wang, Y.
Acuipil, C.
Spreen, W.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 72 - 73
[10] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, Susan
Andrade-Villanueva, Jaime-Federico
Richmond, Gary J.
Rizzardini, Giuliano
Baumgarten, Axel
Masia, Mar
Latiff, Gulam
Pokrovsky, Vadim
Bredeek, Fritz
Smith, Graham
Cahn, Pedro
Kim, Yeon-Sook
Ford, Susan L.
Talarico, Christine L.
Patel, Parul
Chounta, Vasiliki
Crauwels, Herta
Parys, Wim
Vanveggel, Simon
Mrus, Joseph
Huang, Jenny
Harrington, Conn M.
Hudson, Krischan J.
Margolis, David A.
Smith, Kimberly Y.
Williams, Peter E.
Spreen, William R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123

← 1 2 3 4 5 →